Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XZB
|
|||
| Former ID |
DAP000657
|
|||
| Drug Name |
Gefitinib
|
|||
| Synonyms |
Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [1], [2] | |
| Head and neck cancer [ICD-11: 2D42] | Phase 3 | [1], [2] | ||
| Urethral cancer [ICD-11: 2C93; ICD-10: C68.0, C68.1] | Phase 2 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24ClFN4O3
|
|||
| Canonical SMILES |
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
|
|||
| InChI |
1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
|
|||
| InChIKey |
XGALLCVXEZPNRQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 184475-35-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
532631, 7849039, 8035066, 10240807, 10318995, 11377941, 12015033, 14833109, 21317853, 24424016, 24424024, 24424026, 29215403, 29215404, 29303859, 46508649, 47646567, 49635529, 49742641, 50040863, 50100103, 53319998, 53788589, 53799235, 56312091, 56313236, 56313469, 57340492, 61127928, 81092810, 85171051, 92308715, 92717784, 93581024, 99436946, 99444469, 103024897, 103244983, 103905343, 103905344, 104418951, 104829175, 117865087, 118047033, 123105108, 124756943, 124892204, 124892205, 124892206, 125001914
|
|||
| ChEBI ID |
CHEBI:49668
|
|||
| ADReCS Drug ID | BADD_D01008 | |||
| SuperDrug ATC ID |
L01XE02
|
|||
| SuperDrug CAS ID |
cas=184475352
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Gefitinib (adjusted p-values: 2.45E-06). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Gefitinib (adjusted p-values: 2.33E-04). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Gefitinib (adjusted p-values: 1.68E-05). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Gefitinib (adjusted p-values: 1.86E-03). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Gefitinib (adjusted p-values: 1.98E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Gefitinib (adjusted p-values: 6.30E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Gefitinib (adjusted p-values: 1.95E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Gefitinib (adjusted p-values: 3.39E-03). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941). | |||
| REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. | |||
| REF 5 | Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.